DiaMedica Therapeutics Inc. (DMAC) - Dilution Analysis

10-Q filing | 53.8M shares outstanding

10-K filing | 53.9M shares outstanding

8-K filing: DiaMedica Therapeutics Inc. sold 1,501,000 common shares to a healthcare institution fund at $8.10 per share, receiving $12.2 million in gross proceeds on December 19, 2025. ($12.2M proceeds)

10-Q filing | 49.6M shares outstanding

S-3 filing: This S-3 filing describes a potential offering of common shares, warrants to purchase common shares and units with an aggregate offering price not exceeding $100,000,000. The offering may be conducted through underwriters, dealers, agents, or directly to purchasers.

10-Q filing | 51.7M shares outstanding

10-Q filing | 42.8M shares outstanding

10-K filing | 40.4M shares outstanding

10-Q filing | 42.8M shares outstanding

10-Q filing | 42.7M shares outstanding

S-3 filing: This S-3 filing registers for resale 4,720,000 common shares previously issued in a private placement.

8-K filing: DiaMedica Therapeutics Inc. entered into securities purchase agreements to issue 4,720,000 common shares at $2.50 per share in a private placement expected to close on or about June 28, 2024, with gross proceeds of $11.8 million. ($11.8M proceeds)

10-Q filing | 38.0M shares outstanding

S-3 filing: The company is filing an S-3 to offer a combination of common shares, warrants, and units up to an aggregate initial offering price of $100,000,000.

10-K filing | 38.0M shares outstanding

10-Q filing | 37.9M shares outstanding

10-Q filing | 37.9M shares outstanding

S-3 filing: This S-3 filing registers the resale of common shares previously sold in a private placement on June 23, 2023.

8-K filing: DiaMedica Therapeutics Inc. entered into securities purchase agreements to issue 11,011,406 common shares in a private placement at $3.40 per share for most purchasers and $3.91 per share for officers and directors, expecting gross proceeds of $37.5 million. ($37.5M proceeds)

10-Q filing | 26.4M shares outstanding

10-K filing | 26.4M shares outstanding

10-Q filing | 26.4M shares outstanding

10-Q filing | 26.4M shares outstanding

10-Q filing | 26.4M shares outstanding

10-K filing | 26.4M shares outstanding

10-Q filing | 26.4M shares outstanding

S-3 filing: This S-3 filing registers the resale of common shares previously sold in a private placement.

10-Q filing | 18.8M shares outstanding

10-Q filing | 18.8M shares outstanding

S-3 filing: The company may offer to sell any combination of common shares, warrants to purchase common shares, and units comprised of one or more of the other securities described in this prospectus, with an aggregate initial offering price not exceeding $100,000,000.

10-K filing | 18.8M shares outstanding

10-Q filing | 18.7M shares outstanding

10-Q filing | 18.7M shares outstanding

8-K filing: DiaMedica Therapeutics Inc. completed a public offering of 4,000,000 firm shares and an additional 600,000 option shares at $4.70 per share to the underwriters, with a public price of $5.00 per share, resulting in net proceeds of approximately $21.1 million. ($21.1M proceeds)

10-Q filing | 14.1M shares outstanding

10-K filing | 14.1M shares outstanding

8-K filing: DiaMedica Therapeutics Inc. closed a public offering of 2,125,000 shares of its voting common shares at a price of $3.72 per share to the underwriter and $4.00 per share to the public, with net proceeds expected to be approximately $7.7 million. ($7.91M proceeds)

S-3 filing: The filing is an S-3 registration statement indicating the company may offer common shares and other securities through underwriters, dealers, or agents, and describes potential stabilization activities and derivative transactions related to the offering.